Spire Wealth Management Has $92,000 Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Spire Wealth Management decreased its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 84.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,025 shares of the medical equipment provider's stock after selling 5,553 shares during the quarter. Spire Wealth Management's holdings in Lantheus were worth $92,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of LNTH. Wilmington Savings Fund Society FSB acquired a new stake in shares of Lantheus in the third quarter valued at $25,000. Signaturefd LLC lifted its holdings in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 92 shares during the period. UMB Bank n.a. lifted its holdings in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock valued at $47,000 after buying an additional 126 shares during the period. Kathleen S. Wright Associates Inc. acquired a new stake in shares of Lantheus in the third quarter valued at $51,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock valued at $51,000 after buying an additional 146 shares during the period. Institutional investors own 99.06% of the company's stock.

Remove Ads

Lantheus Trading Up 0.2 %

NASDAQ:LNTH traded up $0.18 during mid-day trading on Wednesday, hitting $82.10. 703,995 shares of the company's stock traded hands, compared to its average volume of 793,285. The firm has a 50 day moving average of $91.76 and a two-hundred day moving average of $98.13. Lantheus Holdings, Inc. has a 12 month low of $54.69 and a 12 month high of $126.89. The firm has a market capitalization of $5.71 billion, a price-to-earnings ratio of 13.66 and a beta of 0.44.

Analyst Upgrades and Downgrades

LNTH has been the subject of several research analyst reports. StockNews.com lowered Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Truist Financial restated a "buy" rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. The Goldman Sachs Group initiated coverage on Lantheus in a report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective for the company. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $131.86.

Insider Activity at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.50% of the stock is owned by corporate insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.